SNMX $0.83 +5% > Financial Results: >>
MY NEXT EBIO BCRX KBIO SOME 1000% BIO TECH TURN AROUND INVEST IMHO
Commercial revenues increased 24% to $2.8 million in the second quarter ended June 30, 2017. For the six months ended June 30, 2017, commercial revenues increased 25% to $5.5 million. These improvements primarily resulted from higher direct sales of flavor ingredients to flavor houses and higher royalties from sweet taste boosting ingredients
Financial Outlook:
Senomyx ended the second quarter 2017 with no debt and $11.2 million in cash, an increase of $1.1 million during the second quarter. In addition, the Company is scheduled to receive $14.0 million in committed development funding in the future.
For the third quarter of 2017, the Company expects:
Revenues to be at least $4.7 million, of which at least $2.9 million are commercial revenues; and
Net loss not to exceed $3.2 million or $0.07 per share